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Streptococcus pyogenes (group A streptococci, GAS) is an exclusive human bacterial
pathogen. The virulence potential of this species is tremendous. Interactions with humans
range from asymptomatic carriage over mild and superficial infections of skin and mucosal
membranes up to systemic purulent toxic-invasive disease manifestations. Particularly
the latter are a severe threat for predisposed patients and lead to significant death tolls
worldwide. This places GAS among themost important Gram-positive bacterial pathogens.
Many recent reviews have highlighted the GAS repertoire of virulence factors, regulators
and regulatory circuits/networks that enable GAS to colonize the host and to deal with
all levels of the host immune defense. This covers in vitro and in vivo studies, including
animal infection studies based on mice and more relevant, macaque monkeys. It is now
appreciated that GAS, like many other bacterial species, do not necessarily exclusively
live in a planktonic lifestyle. GAS is capable of microcolony and biofilm formation on host
cells and tissues. We are now beginning to understand that this feature significantly
contributes to GAS pathogenesis. In this review we will discuss the current knowledge
on GAS biofilm formation, the biofilm-phenotype associated virulence factors, regulatory
aspects of biofilm formation, the clinical relevance, and finally contemporary treatment
regimens and future treatment options.
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INTRODUCTION
Streptococcus pyogenes belongs to the serological group A among
the streptococci (group A Streptococcus, GAS) and is an exclu-
sively human pathogen. GAS causes significant disease worldwide
and adds a large burden to national health care systems (Tan
et al., 2014). An excellent compilation of data and estimates of
the global burden of GAS diseases from 2005 revealed 616 million
cases of pharyngitis, 111 million cases of pyoderma and at least
517,000 deaths due to severe invasive diseases and sequelae. This
dataset is manifesting the important status of GAS among bacte-
rial pathogens and is an impressive documentation of GAS impact
on global mortality and morbidity (Bisno et al., 2005; Carapetis
et al., 2005; Ralph and Carapetis, 2013).
Entry ports for GAS after person to person transmission are
oral cavity, skin and wounds. In particular, mucosal membranes
of the oropharynx and non-intact skin are preferred colonization
sites (Cunningham, 2000; Tan et al., 2014). In otherwise healthy
individuals, GAS usually causes mild and self-healing purulent
infections of mucosal membranes and skin, such as pharyn-
gitis, impetigo and pyoderma. In patients with predispositions
such as immune-suppression, diabetes and related diseases, or
specific HLA-DR (MHC class II cell surface receptor) subtypes,
occasionally severe and invasive life-threatening diseases occur.
Necrotizing fasciitis and streptococcal toxic shock syndrome
belong to these disease manifestations with high morbidity and
mortality rates. Antibiotic therapy is mandatory, even for uncom-
plicated primary infections, to prevent secondary autoimmune
sequelae like rheumatic heart disease or glomerulonephritis
(Cunningham, 2000).
GAS is well adapted to its human host, since it is equipped with
a large set of virulence factors of all classes. The bacteria express
surface proteins and secreted factors leading to (i) immunoglob-
ulin and complement factor degradation (EndoS, Mac, C5a pep-
tidase) and (ii) general complement inhibition (achieved byM
protein, capsule expression and Sic), (iii) extracellular matrix
and serum protein binding via multiple MSCRAMMS (micro-
bial surface components recognizing adhesive matrix molecules)
(M protein, Cpa, Eno, Epf, up to five different firbronectin-
binding MSCRAMMS), (iv) dysregulation of coagulation (plas-
minogen/plasmin binding, streptokinase Ska activity), and (v)
cytotoxic and cytolytic activity toward various host cell types
(Nga, SLS, SLO). Depending on the presence of phage-related
chromosomal islands as variable parts of the accessory genome
in the different GAS serotypes, a variable number of superanti-
gens (SpeA-J, SmeZ) is expressed and secreted (Banks et al., 2002;
Spaulding et al., 2013).
The presence of individual genes encoding virulence factors is
GAS serotype-specific and expression depends on environmental
conditions. Transcriptional changes during GAS cultivation and
pathogenesis were recently reviewed (Fiedler et al., 2010). A most
recent review highlights the importance of GAS virulence factors
for disease manifestation and pathogenesis (Walker et al., 2014).
As successful pathogen, GAS tightly controls virulence factor gene
expression to keep the number of exposed proteins for immune
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recognition to a minimum. Regulation occurs on multiple levels
including the activity of stand-alone transcription regulators and
two component signal transduction systems (Kreikemeyer et al.,
2003; Patenge et al., 2013), catabolite control (Almengor et al.,
2007), control of mRNA decay (Bugrysheva and Scott, 2010), cis-
or trans-acting regulation of small non-coding RNAs (Patenge
et al., 2013), and quorum sensing (Jimenez and Federle, 2014).
How these regulators interact under in vitro, in vivo-like, and host
infection conditions, and how their activities are hierarchically
clustered is currently studied intensively (McIver, 2009; Fiedler
et al., 2010; Patenge et al., 2013). Information about these regu-
latory processes allows a better understanding of GAS pathogenic
mechanisms and could identify novel levels for interference with
anti-infectiva to prevent and/or cure GAS infections.
Apart from the well-studied GAS virulence traits and patho-
genesis mechanisms, like host cell adherence/internalization,
phagocytosis resistance, escape from phagocytic killing, host cell
apoptosis induction and autophagy escape (Walker et al., 2014),
the ability of GAS to form micro-colonies and matured biofilms
in vitro and in vivo was just recently appreciated. Biofilms, due
to their composition, physiology and physical parameters present
a massive danger signal. The host immune defense interacts on
all levels to attack these 3 dimensional foreign structures. Some
of the above listed genes encoding virulence factors and regula-
tors moved into the focus of GAS biofilm investigation and are
discussed in this review.
Furthermore, the specific features of biofilms, i.e., the 3-
dimensional structure, the matrix of extracellular polymeric sub-
stances, and the lower growth rates and differences in metabolism
of the bacteria, cause problems in efficient antibiotic treatment of
GAS organized in such structures. Therefore, in this review, we
will also discuss potential alternatives to antibiotic treatment of
GAS biofilms.
CLINICAL RELEVANCE OF GAS BIOFILMS
GAS was considered a classical extracellular human pathogen
for a long time. Numerous studies have evaluated the poten-
tial of these bacteria to adhere to and internalize into almost all
host cell types, a feature which was discussed as reason for the
occurrence of recurrent GAS infections (Facinelli et al., 2001;
Podbielski and Kreikemeyer, 2001). However, now it is under
debate if recurrence is sufficiently explained by GAS host cell
adherence/internalization or if GAS biofilms play a so far under-
appreciated role. Moreover, the question if GAS biofilms are clin-
ically relevant needs to be addressed. Here we discuss this aspect
with a careful look on terminology (microcolony vs. biofilm) and
in vitro vs. in vivo observations and studies.
Particularly the in vitro biofilm phenotype was evalu-
ated with isolate collections and for many of the clinically
relevant/predominant GAS serotypes under static and flow
conditions. In these studies, a significant heterogeneity of this
phenotype was noted among strains of a particular serotype
(Lembke et al., 2006). Another study revealed 90% of GAS
serotypes, from invasive and non-invasive infections, to form
biofilms, thereby supporting the notion that this is a trait of indi-
vidual strains rather than a general serotype attribute (Baldassarri
et al., 2006). Moreover, a reduced capacity to internalize into
host cells in combination with macrolide-susceptibility was sug-
gested as a strong reason for a biofilm-positive phenotype, as this
is a means of protection from antibiotic treatment (Baldassarri
et al., 2006). Together these and other facts suggested inclusion
of biofilm phenotype data into epidemiological investigations of
GAS (Köller et al., 2010).
Generally, two different entry ports could give rise to micro-
colony formation and the biofilm phenotype. First, GAS can enter
new hosts via the oral cavity and establish in the upper respi-
ratory tract. Here, in particular GAS pharyngitis is associated
with antibiotic treatment failure leading to multiple infection
episodes in affected patients (Facinelli et al., 2001; Podbielski
and Kreikemeyer, 2001). Isolates from such cases have a higher
tendency toward resistance against macrolide antibiotics in asso-
ciation with the presence of protein F1, a virulence factor sup-
porting host cell internalization (Facinelli et al., 2001). This
observation sustains the theory that GAS have an intracellu-
lar sanctuary where they persist and hide from eradication by
antibiotic treatment and host defense mechanisms. Conley and
colleagues rather related antibiotic treatment failure with biofilm
formation capacity of GAS (Conley et al., 2003). They showed
pharyngitis treatment failure patient isolates to have a biofilm-
positive phenotype and increased MBEC (minimum biofilm
eradication concentration) for all contemporary antibiotics used
to treat acute pharyngitis cases. Moreover, GAS biofilms were
found in tonsillar reticulated crypts, isolated from tonsillec-
tomy material (Roberts et al., 2012). Thus, there is a clear
link between GAS caused pharyngitis and biofilm formation
capacity.
Second, also human skin acts as entry port for these pathogens.
Skin from patients with impetigo and atopic dermatitis is a habi-
tat for GAS microcolonies and biofilms (Hirota et al., 1998;
Akiyama et al., 2003). Whether GAS microcolonies represent a
specific physiological state with own existence or rather a pre-
stage of “mature” biofilm is currently unclear. The latter is likely,
as microcolonies are surrounded by a FITC-ConA stainable glyco-
calyx (Akiyama et al., 2003). Cho and Caparon clearly pointed out
that GAS forms biofilm-like bacterial communities during soft
tissue infection in zebrafish, which largely differ in gene expres-
sion patterns from GAS biofilms on abiotic surfaces (Cho and
Caparon, 2005).
Further in vivo evidence from animal models revealed GAS
biofilm formation during otitis media in a chinchilla middle ear
infection model. However, biofilm formation was not strictly
required for infectivity (Roberts et al., 2010a). In clinical stud-
ies in 37% of all non-severe recurrent acute otitis media (RAOM)
cases in children GAS was identified as nasopharyngeal biofilm-
producing otopathogen (Torretta et al., 2012). The final and
most critical development step of biofilm lifestyle is the disper-
sal stage, which could transform mild and local infections into
severe-disseminating diseases (Connolly et al., 2011a).
Apart from the accumulating data on GAS biofilm-mediated
antimicrobial resistance toward contemporary antibiotics, lead-
ing to treatment failure and recurrent infection episodes, the
fact that biofilm grown GAS are naturally competent and thus
transformable with foreign DNA (Marks et al., 2014) is of major
clinical relevance and concern.
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CONCLUSION
Although the GAS biofilm phenotype just recently moved into
the focus of research, quite a substantial number of studies col-
lected in vitro, but more importantly, also in vivo evidence that
this GAS lifestyle contributes to many diseases caused by GAS.
As outlined above, there is in particular compiling data for a role
of GAS biofilms during infection of oto-, nasopharyngeal-, and
skin-localized human diseases. Thus, the question on the clinical
relevance of GAS biofilms is no longer disputable. However, there
is a strong requirement for intensification of research in this area
and elucidation of better treatment options.
VIRULENCE FACTORS ASSOCIATED WITH THE GAS BIOFILM
PHENOTYPE
To date, more than 50 virulence factors have been described
in GAS. Their expression is tightly regulated and fine-tuned in
dependence on growth phase and environmental conditions of
the bacteria (Fiedler et al., 2010). Consequently, also the biofilm
lifestyle of GAS is associated with a specific pattern of virulence
factor expression that differs from that of planktonic GAS.
Since biofilm formation in general comprises at least three
distinct stages—i.e., (i) initial adherence and microcolony for-
mation, (ii) biofilm maturation with production of a matrix of
extracellular polymeric substances (EPS), and (iii) detachment of
sessile cells—it is not unexpected that virulence factor expression
patterns differ in these respective stages (O’Toole et al., 2000).
TRANSCRIPTOME STUDIES ON GAS BIOFILMS
The only transcriptome study on GAS biofilms available so far
has been carried out with the GAS HSC5 M14 serotype strain.
Here, transcript levels in biofilm bacteria were compared to those
of planktonic cells in the exponential and stationary growth
phase. This analysis revealed an increased abundance of speB
and spd/mf transcripts and a lower abundance of ska mRNA
in biofilm GAS than in bacteria from the exponential phase of
planktonic cultures. WhileM protein expression was more or
less constant in biofilm formation, the capsule biosynthesis genes
were slightly induced in the maturation phase (Cho and Caparon,
2005). Cho and Caparon propose that in later stages carbohydrate
metabolism and capsule biosynthesis are essential to establish a
solid biofilm with bacteria encased in a robust matrix of extracel-
lular polysaccharides (Cho and Caparon, 2005). In S. pyogenes,
the main sugar components in the matrix are L-glucose and
D-mannose (Shafreen et al., 2011).
The data of this study are somewhat contradictory to a later
work, where expression of several virulence genes in biofilm and
planktonic bacteria of the M3 GAS strain MGAS315 has been
assessed by qPCR. In contrast to the work of Cho and Caparon,
biofilms and planktonic bacteria were exposed to keratinocytes.
When grown as biofilms on live keratinocytes for 48 h, down-
regulation of genes for streptolysins (sagA, slo), hyaluronic acid
capsule biosynthesis (hasA), M-protein (emm3) and the cysteine
protease SpeB (speB), was observed while competence-associated
com genes were upregulated in comparison to planktonic cells
exposed to epithelial cells (Marks et al., 2014).
With these limited data sets of only two GAS serotypes and
the differential setup of the biofilm assays in the studies of Cho
and Caparon (2005) and Marks et al. (2014) it is not possible
to deduce any biofilm specific transcriptome yet. Similar stud-
ies including more serotypes are needed. Having in mind that
the ability to grow in biofilms is rather a strain specific trait and
not a GAS serotype attribute (Baldassarri et al., 2006; Köller et al.,
2010) it is questionable if a general biofilm transcriptome can be
elucidated.
MSCRAMMS
It has early been recognized that GAS biofilm formation is
largely varying between different strains. Certain GAS strains
are able to bind to abiotic polystyrene surfaces, while other
strains need matrix or serum protein coated surfaces to estab-
lish biofilms or are unable to produce biofilms at all (Conley
et al., 2003; Lembke et al., 2006). Obviously, adhesive surface
structures are needed in GAS biofilms to mediate autoaggre-
gation and attachment of the bacteria to the biotic or abiotic
surface (Manetti et al., 2007; Courtney et al., 2009; Oliver-
Kozup et al., 2011, 2013). E.g., various GAS strains, representing
8 emm types, likely associated with at least 6 different FCT
(fibronectin-binding, collagen-binding, T-antigen)-types, have
been shown to lose their ability to form biofilms when treated
with trypsin, thereby removing trypsin-sensitive surface proteins
(Courtney et al., 2009).
Biofilm formation ability of GAS strains seems to be associ-
ated with certain M- and FCT-types. This indicates that adhesion
and co-aggregation processes mediated by M- or M-like proteins
and/or FCT region-encoded pili are essential for the successful
establishment of biofilms (Lembke et al., 2006; Manetti et al.,
2007, 2010; Edwards et al., 2008; Köller et al., 2010).
To date, 9 different types of FCT regions with distinct archi-
tectures are described in GAS (Kratovac et al., 2007; Falugi et al.,
2008). The FCT region encoded core pilus operon comprises
genes for a pilus backbone protein, at least one matrix protein
binding ancillary protein, sortases (SrtB/SrtC2), and a signal pep-
tidase (Kratovac et al., 2007; Kreikemeyer et al., 2011). There is
clear evidence hinting at an association between FCT type and
biofilm formation (Köller et al., 2010; Manetti et al., 2010). While
FCT type 1 strains were shown to be generally good biofilm for-
mers, independent of media or pH-conditions, FCT-9 strains are
poor biofilm formers under all conditions tested so far. In strains
with other FCT types, e.g., FCT-2, FCT-3, FCT-5, and FCT-6,
biofilm production depends on culture conditions and is trig-
gered by low pH, e.g., caused by sugar metabolism in unbuffered
media (Figure 1). FCT type 4 strains show an inhomogeneous
response to environmental conditions with respect to biofilm
formation. Generally, M28 and M89 strains tested were poor
biofilm formers under all conditions, while M12 strains showed a
medium and pH dependent biofilm formation (Köller et al., 2010;
Manetti et al., 2010). The specific differences in involvement of
pilus structures in biofilm formation in different FCT-type strains
might in part be attributed to the high diversity in amino acid
sequence of the pilus backbone proteins, which can vary among
as well as within FCT-types (Falugi et al., 2008). E.g., T6 type
pilus backbone proteins, which can be found in M6/FCT-type
1 strains, seem to strongly promote biofilm formation (Kimura
et al., 2012). It has also been demonstrated that ancillary pilus
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FIGURE 1 | Three-dimensional images of biofilms of various GAS
emm/FCT types grown in C-medium in the absence or presence of
glucose. Cells were stained with Alexa Fluor 647 and visualized via
Confocal Laser Scanning Microscopy (CLSM); magnification 600 times; box
size 13.8 × 13.8µm. Left panel: non-supplemented C-medium. Right
panel: C-Medium supplemented with 30mM glucose. Strain names,
emm-types, and FCT types are given in the middle column.
proteins such as Ancillary protein 1 are necessary for biofilm
formation (Becherelli et al., 2012).
FCT-region encoded pili are obviously necessary for biofilm
formation, but other factors are needed as well, since several
GAS strains expressing functional pili in moderate levels are
still unable to form biofilms. In contrast, GAS strains with low
pilus expression or with defective pili are generally poor biofilm
formers (Manetti et al., 2007). As mentioned above, these addi-
tional factors are most likely M- and M-like proteins, but also
other surface adhesins such as the fibronectin binding proteins
PrtF2 and Scl1, or the AgI/II type polypeptide AspA (Cho and
Caparon, 2005; Luo et al., 2008; Courtney et al., 2009; Maddocks
et al., 2011; Oliver-Kozup et al., 2013). It has been proposed
that M- or M-like proteins are needed for LTA-stabilization,
thereby increasing hydrophobicity on the GAS surface, which
facilitates autoaggregation and adhesion to biotic and abiotic sur-
faces and consequently biofilm formation (Cho and Caparon,
2005; Courtney et al., 2009). This is supported by the finding that
most M- and M-like protein defective mutants show decreased
biofilm formation and lower hydrophobicity compared to their
wild type parent strains (Cho and Caparon, 2005; Courtney et al.,
2009).
The cell wall anchored adhesion AgI/II type polypeptide AspA
has been shown to mediate GAS M28 biofilm formation on saliva
coated surfaces (Brady et al., 2010; Maddocks et al., 2011, 2012;
Hall et al., 2014). AgI/II type proteins bind to salivary glycopro-
teins. In GASM28AspA is proposed tomediate biofilm formation
by direct protein-protein interaction with the salivary glycopro-
tein gp-340 (Maddocks et al., 2011). This is supported by the fact
that AspA deficient mutants of GAS M28 show an about 50%
reduced biofilm mass when cultivated on gp-340 or saliva-coated
surfaces. On uncoated polystyrene surfaces biofilms of AspA
mutants resembled those of the cognate WT strains (Maddocks
et al., 2011).
The collagen-like protein Scl1 binds cellular fibronectin and
also mediates biofilm formation (Caswell et al., 2010; Oliver-
Kozup et al., 2011, 2013). M3 strains intrinsically harboring a
scl1 gene with a mutation that results in production of a trun-
cated Scl1 protein where shown to be unable to form biofilms
on abiotic surfaces. M41, M28, and M1 strains with scl1 dele-
tions showed a decreased biofilm formation compared to their
cognate wild types. S. pyogenes Scl1 expressed on the surface of
the heterologous host Lactococcus lactis enables biofilm forma-
tion of this bacterium (Oliver-Kozup et al., 2011). Considering
its specific binding to cellular fibronectin, Scl1 might be of spe-
cial importance for microcolony/biofilm formation of GAS in
wounds (Oliver-Kozup et al., 2013).
Apparently, a critical amount (or number?) of surface associ-
ated adhesive structures is necessary to mediate initial adherence
and autoaggregation of the bacteria. As mentioned above, struc-
tures potentially involved are pili, M- or M-like proteins, PrtF2,
Scl1, or AspA. The importance of the respective structures in dif-
ferent GAS strains/M-serotypes/FCT-types obviously differs. Also
regulatory mechanisms are not ubiquitous among GAS strains.
While in some strains environmental signals such as a low pH
are needed to induce biofilm formation, other strains produce
biofilms in a pH-independent manner. It is likely that some of
the adhesive structures are more important to mediate the ini-
tial adherence to abiotic surfaces while others will be crucial for
adherence to biotic structures. For sure the latter will be of more
significance in the patient. A concerted investigation of all sur-
face structures mentioned above in terms of the involvement in
biofilm formation on biotic surfaces is still missing.
SpeB AND OTHER SECRETED ENZYMES
The streptococcal pyogenic exotoxin B (SpeB) and other secreted
enzymes are associated with the biofilm lifestyle of GAS. SpeB
as a secreted cysteine protease is suspected to degrade peptides
that stabilize the biofilmmatrix (Roberts et al., 2010a,b; Connolly
et al., 2011a,b). It has been shown that in the M1 serotype strain
MGAS5005 SpeB activity is negatively correlated with biofilm
production. While regulator mutants with high SpeB production
(MGAS5005srv) are completely unable to form biofilms, dele-
tion of speB in these strains reconstitutes the biofilm phenotype
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of the wild type strain. Also chemical inhibition of SpeB activ-
ity increases biofilm masses of MGAS5005srv (Roberts et al.,
2010a,b). Furthermore, the external addition of active SpeB
to MGAS5005 cultures significantly inhibits biofilm formation
(Roberts et al., 2010b).
In line with these data, downregulation of speB expression has
been observed in biofilms of an M3 serotype strain compared to
planktonic bacteria (Marks et al., 2014).
Next to SpeB, other secreted enzymes might be critical
for biofilm formation. Proteases and nucleases that potentially
degrade components of the extracellular matrix need to be sup-
pressed to maintain the structural integrity of GAS biofilms.
While in other streptococci such as S. intermedius, S. mutans, or
S. pneumoniae, extracellular DNA (eDNA) is a structural com-
ponent of biofilm matrix, there is no direct prove for eDNA in
GAS biofilms yet (Whitchurch et al., 2002; Montanaro et al., 2011;
Domenech et al., 2012). However, increased secretion of enzyme
degrading matrix components at a certain point in time might
promote dispersion of GAS biofilms and thereby facilitate distri-
bution of GAS within the host. This hypothesis is supported by
the data of Cho and Caparon, who found high speB expression
levels in mature biofilms compared to planktonic bacteria of the
HCS5 M14 GAS strain (Cho and Caparon, 2005).
CAPSULE
The role of the hyaluronic acid capsule in GAS biofilms is not
entirely clear yet. There are somewhat contradictory observations
described by different groups. Cho and Caparon observed a slight
induction of capsule biosynthesis gene (has-operon) transcripts
in GAS strain HSC5 during biofilm maturation. Furthermore,
they found a mutant defective of capsule biosynthesis to be
unable to form a solid biofilm under flow conditions, while
under static conditions the biofilm masses were unaffected by
this mutation (Cho and Caparon, 2005). Marks and colleagues
on the other hand described a decrease in hasA transcription
in biofilms of MGAS315 (M3) on keratinocytes in comparison
to keratinocyte-exposed planktonic bacteria (Marks et al., 2014).
Furthermore, there is indirect evidence that capsule production
inhibits biofilms, since it has been shown for several GAS strains
that covS deletion leads to an increased capsule production but
also to lower biofilm biomasses (Sugareva et al., 2010). Initially,
a thick capsule might mask adhesive surface structures, thereby
preventing adhesion and co-aggregation of the bacteria, which
would probably rather inhibit biofilm formation. In later stages
of biofilm maturation, capsule production could be involved in
establishing a robust biofilm matrix, as suggested by Cho and
Caparon (2005).
CONCLUSION
From all studies introduced above theM protein as one major vir-
ulence determinant of GAS seems to support biofilm formation,
but secreted proteins and capsule could impair biofilm formation.
However, it has to be kept in mind that the data discussed here
are all based on in vitro experiments that most likely only poorly
resemble the in vivo situation. Most of the experimental data are
based on biofilms formed on abiotic plastic surfaces, sometimes
coated with matrix or serum proteins. Only few studies analyzed
biofilms grown on epithelial cells (Fiedler et al., 2013; Marks
et al., 2014). To our knowledge, device-associated GAS biofilms
have never been described in patients. Furthermore, although
GASmicrocolony formation in the oropharynx has been observed
(Diaz et al., 2011; Roberts et al., 2012; Torretta et al., 2012; Woo
et al., 2012), it is yet not known whether complex biofilms—as
they can be obtained in vitro—are actually occurring in patients.
Therefore, taken together, the relevance of these in vitro data for
real infections in patients remains unclear.
REGULATORY ASPECTS OF GAS BIOFILMS
The biofilm lifestyle is associated with broad transcriptional
changes, affecting the expression levels of about 25% of the
GAS genes (Cho and Caparon, 2005). Several transcriptional
regulators were shown to be involved in and crucial for the estab-
lishment and maintenance of biofilms. From the data available
to date, three major regulatory processes can be deduced that
facilitate the biofilm lifestyle of GAS:
(i) Peptide pheromone based quorum sensing mediated by
the short hydrophobic peptides SHP2/SHP3 (Chang et al.,
2011).
(ii) Repression of secreted and surface associated enzymes such
as the cysteine protease SpeB and other proteases and nucle-
ases (Dmitriev et al., 2008; Roberts et al., 2010a; Connolly
et al., 2011a; McDowell et al., 2012).
(iii) Induction of surface associated autoaggregative and adhe-
sive structures such as M- and M-like proteins and the FCT
region encoded pilus (Cho and Caparon, 2005; Luo et al.,
2008; Manetti et al., 2010).
The major players and the regulatory network contributing to
GAS biofilm formation are summarized in Figure 2.
QUORUM SENSING
Quorum sensing mechanisms are crucial for biofilm forma-
tion in many organisms. In GAS, four different ways of
inter- and intraspecies communication are described, i.e., Rgg-,
Sil-, lantibiotics-, and LuxS/Autoinduer-2-dependent processes
(Jimenez and Federle, 2014).
In GAS, biofilm formation is associated with peptide-
pheromone based quorum sensing mediated by the short
hydrophobic peptide (SHP) pheromones SHP2 and SHP3. These
peptide pheromones are encoded downstream of two genes
encoding for the Rgg-like transcriptional regulators Rgg2 and
Rgg3, respectively (Chang et al., 2011; Federle, 2012; Lasarre
et al., 2013; Aggarwal et al., 2014). The propeptides are secreted
and processed to the mature peptide pheromones SHP2C8 and
SHP3C8, which are taken up into GAS via the oligopeptide per-
mease Opp. The transcription of both peptide pheromone genes
shp2 and shp3 is inhibited as long as Rgg3 is bound to the respec-
tive promoters. SHP2C8 and SHP3C8 bind to Rgg3 and Rgg2,
leading to a dissociation of Rgg3 from and binding of Rgg2 to the
shp2 and shp3 promoters. In a positive feedback loop, this induces
the expression of shp2 and shp3 (Chang et al., 2011; Aggarwal
et al., 2014). In GAS M49 NZ131 it has been shown that SHP2/3
dependent activation via Rgg2 induces biofilm production, while
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FIGURE 2 | Regulatory network involved in GAS biofilm formation.
Arrow heads indicate direct or indirect induction, blocked lines indicate
direct or indirect repression, dashed lines indicate export out of the
bacterial cell, and dotted lines indicate ambiguous effects. Outer circle (light
blue): transcriptional regulation level; Inner circle (darker blue):
biofilm-associated virulence factors; Outside: environmental conditions and
quorum sensing peptides influencing the biofilm phenotype. “?” stands for
unknown Regulator/regulatory mechanism.
Rgg3 represses biofilms via repression of SHP2/3 production. It
is not known to date, which transcriptional changes are caused
by the SHP2/3 dependent activation of Rgg2 and inactivation of
Rgg3 that finally lead to biofilm formation. Furthermore, it has
not been elucidated yet whether this system also controls biofilm
formation in other GAS strains, but in silico analyses show that
Rgg2 and Rgg3 are present in all GAS strains (Chang et al., 2011).
Two of the other above-mentioned quorum sensing systems
of GAS have been associated with the GAS biofilm lifestyle as
well. For an M18 strain it could be shown that a SilC deletion
mutant was significantly impaired in biofilm formation (Lembke
et al., 2006). Furthermore, there are hints that LuxS is involved in
the control of SpeB production and emm gene expression, which
could influence biofilm formation (Lyon et al., 2001;Marouni and
Sela, 2003; Siller et al., 2008; Beema Shafreen et al., 2014). Both of
the latter QS systems have not been investigated in the context
of GAS biofilm in detail yet. For more details on GAS quorum
sensing please refer to a current review by Jimenez and Federle
(Jimenez and Federle, 2014).
TRANSCRIPTIONAL REGULATORS OF SpeB AND OTHER SECRETED
ENZYMES
Since SpeB activity leads to dispersal of biofilm structures and
prevents biofilm formation in GAS, repression of speB transcrip-
tion is necessary for successful biofilm establishment (Doern
et al., 2009). Therefore, regulators involved in transcription of
speB also control biofilm formation in GAS. Transcriptional reg-
ulation of SpeB is quite complex and involves direct and indirect
actions of numerous GAS regulators, as recently reviewed by
Carroll and Musser (2011). Positive regulators directly acting at
the promoter of the speB gene are RopB, another member of the
Rgg-regulator family also referred to as Rgg1 (Chaussee et al.,
1999; Neely et al., 2003; Dmitriev et al., 2008; Hollands et al.,
2008), and the sugar metabolism regulator CcpA (Kietzman and
Caparon, 2010; Shelburne et al., 2010). Consequently, deletion of
the ropB gene leads to lower speB expression and an increased
biofilm formation as shown in the M49 NZ131 strain (Chang
et al., 2011). To our knowledge, for CcpA an influence on biofilm
formation has not been elucidated yet.
The CovR (aka CsrR) response regulator of the CovRS two
component system probably binds directly to the speB promoter
as well, acting as a transcriptional repressor (Miller et al., 2001).
Consequently, repression of speB transcription by CovR enables
GAS biofilm formation. CovRS influence on biofilm formation
seems to be serotype or even strain dependent. It has been shown
that deletion of the sensor kinase CovS leads to decreased biofilm
formation inmost strains tested. However, for someM6 strains an
increased biofilm formation has been observed in CovS deletion
strains (Hollands et al., 2010; Sugareva et al., 2010). Furthermore,
it was shown that a mutant of the HSC5 strain lacking the CovR
response regulator is unable to form biofilm at all (Cho and
Caparon, 2005).
Another virulence-associated regulator, Srv, is involved in con-
trol of of speB expression via indirect mechanisms (Reid et al.,
2004; Doern et al., 2009; Roberts et al., 2010a; Connolly et al.,
2011a).The deletion of srv in theM1T1 strainMGAS5005 leads to
an increased activity of SpeB and therefore to loss of the biofilm
phenotype (Reid et al., 2006; Doern et al., 2009). In Western Blot
analyses SpeB could not be detected in MGAS5005 biofilms after
24 h growth, whereas in the srv deletion mutant high amounts of
SpeB are present in cultures after 24 h growth (Doern et al., 2009).
The Srv mediated repression of SpeB activity is not restricted to
the MGAS5005 strain, which has a naturally occuring mutation
that leads to an inactive CovS sensor kinase. The effects of Srv on
SpeB and biofilm production have also been observed for other
GAS strains, although effects of srv deletion are not as drastic in
those strains as they are in MGAS5005 (Connolly et al., 2011a).
Another regulator potentially involved in biofilm formation is
CodY, a regulator involved in the response to nutrient depriva-
tion in many gram positive bacteria (Sonenshein, 2005). CodY
deletion mutants were shown to have a reduced biofilm forma-
tion capacity of GAS in chemically defined medium (McDowell
et al., 2012). This effect probably also results from the indirect
CodY-mediated repression of the production of SpeB and other
secreted proteases and nucleases (McDowell et al., 2012).
TRANSCRIPTIONAL REGULATION OF BIOFILM-RELEVANT MSCRAMMS
The transcriptional regulation of GAS surface associated adhesins
has been subject to extensive investigations and the regulatory
networks have often been reviewed in the past (Kreikemeyer et al.,
2003; Hondorp and McIver, 2007; McIver, 2009; Fiedler et al.,
2010). Nevertheless, only few of the regulators involved have
been investigated with respect to their impact on biofilm forma-
tion. Since biofilm formation is apparently associated with the
pilus and the M-protein family, it is quite obvious that transcrip-
tional regulators influencing the expression of the FCT region
encoded pilus genes and the emm gene should influence biofilm
formation in GAS. Mga is the major stand-alone transcriptional
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positive regulator of emm and emm-like genes (Hondorp and
McIver, 2007). Consequently, Mga inactivation leads to a loss of
autoaggregation and biofilm formation capacity in GAS (Cho and
Caparon, 2005; Luo et al., 2008). Regulation of Mga itself is very
complex and was recently reviewed (Hondorp and McIver, 2007;
Patenge et al., 2013).
For some strains, i.e., those harboring an FCT-2, -3, or -4 type
pilus encoding region, one of the major environmental signals
driving biofilm formation is the external pH, as shown exemplar-
ily for an FCT type 3 strain in Figure 3. In these strains, pilus
expression is induced under acidic conditions. In contrast, FCT-1
strains produce pH-independent biofilms and do not show any
pH-dependent differences in pilus gene expression (Köller et al.,
2010; Manetti et al., 2010). The regulator(s) mediating the pH-
driven expression of the pilus genes are not known yet. It is likely
that the FCT-region encoded RofA-like regulators RofA or Nra
might be involved, although this has not been experimentally
proven yet (Kreikemeyer et al., 2002, 2011).
Conclusion
Environmental signals such as low pH and critical levels of pep-
tide pheromones initiate complex regulatory circuits leading to
biofilm formation in GAS. The details in environmental trig-
gers, transcriptional changes, and regulators involved seem to be
strain-specific and are not completely understood yet.
TREATMENT OF GAS BIOFILMS—CLINICAL AND
EXPERIMENTAL ASPECTS
Penicillin remains the most important therapeutic agent to med-
icate GAS skin and upper respiratory tract infections such as
impetigo, erysipelas, cellulitis, tonsillitis, pharyngitis, or scar-
let fever (Bisno et al., 2002; Shulman et al., 2012). Fortunately,
there is no confirmed case of beta-lactam resistant GAS to
date. Patients with penicillin intolerance can be treated with
FIGURE 3 | Confocal Laser Scanning micrographs of 24h emm3/FCT-3
GAS strain HRO-K-044 biofilms cultured in alkalined or acidified
C-medium. Cells were stained with live/dead dye containing Syto9 and
Propidiumiodide. Magnification 630 times; box size: 19.8 × 19.8µm. Left
panel: mature biofilm grown in C-medium with initial pH of 8.5. Right
panel: mature biofilm grown in C-medium with initial pH of 6.5. Upper row:
45◦ perspective. Lower row: top view.
cephalosporins ormacrolides such as erythromycin, azithromycin
or clarithromycin instead. Of note, increasing numbers of infec-
tions with macrolide-resistant strains are reported, ranging up to
38% of erythromycin resistant isolates (Syrogiannopoulos et al.,
2001; Sauermann et al., 2003; Richter et al., 2005; Ardanuy et al.,
2010; Rubio-Lopez et al., 2012). This leads to a decrease in suit-
ability of this agent class for calculated treatment of local GAS
infection.
Severe systemic GAS infections such as sepsis, necrotizing
fasciitis or streptococcal toxic shock like syndrome (STSS) are
most commonly treated utilizing penecillin in combination with
clindamycin. The combination with clindamycin proved to be
beneficial to prevent GAS toxin production during therapy
(Zimbelman et al., 1999; Russell and Pachorek, 2000).
Although there seems to be no naturally occurring penicillin
resistant GAS isolates, it was stated that in about 30% of GAS
infections the pathogens are not completely eradicated despite
adequate antibiotic therapy and general susceptibility of the GAS
isolates (minimal inhibitory concentration [MIC] ≤ 0.25mg/L),
potentially resulting in recurrent infections and persistent car-
riage (Conley et al., 2003; Baldassarri et al., 2006; Ogawa et al.,
2011). There are two explanations discussed in the literature.
On the one hand, intracellular persistence of GAS could prevent
successful eradication of the bacteria by antibiotic treatment of
the patients (Podbielski and Kreikemeyer, 2001). On the other
hand, biofilms are discussed to be a cause for treatment failure.
It was shown that GAS isolates organized in biofilm-structures
could suffer penicillin concentrations up to 400mg/l (minimum
biofilm eradication concentration [MBEC] ≥ 400mg/L). This
exceeds the usual MICs by far, displaying clinical resistant lev-
els (Conley et al., 2003; Baldassarri et al., 2006; Lembke et al.,
2006; Shen et al., 2013). Hence, GAS organized in biofilm struc-
tures are able to survive antibiotic treatment that is adequate for
planktonic GAS. To reach a better clinical outcome and lower
treatment failure rates, it would be necessary to adapt treatment
of GAS infections to achieve an effective degradation of biofilm
structure.
EXPERIMENTAL APPROACHES OF GAS BIOFILM TREATMENT
Degradation of bacterial biofilm structures can be achieved by
treatment with endolysins. This has been reported for several
gram positive pathogens, e.g., Staphylococcus aureus, Streptococcus
pneumoniae, Bacillus antracis, Streptoccus suis (Loeffler et al.,
2001; Schuch et al., 2002; Becker et al., 2008; Domenech et al.,
2011). Even species with a high tendency to multiple antibiotic
resistances can be efficiently killed by such lysins.
For degradation of GAS biofilms, the streptococcal-specific
bacteriophage C1 encoded bacteriophage lysin C (PlyC) is
of special interest. It was shown that this multimeric N-
acetylmuramoyl-L-alanine amidase hydrolyzes GAS cell walls and
eliminates bacterial cells in vitro and in vivo (Krause, 1957;
Fischetti et al., 1971; Raina, 1981; Loeffler et al., 2001; Nelson
et al., 2001, 2006; Köller et al., 2008). Shen and colleagues further-
more demonstrated PlyC to degrade both GAS biofilm structures
and biofilm associated cells efficiently, thereby affecting GAS
biofilms significantly more than penicillin (Shen et al., 2013).
These abilities make PlyC a reasonable candidate supplement
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for therapeutic treatment of GAS infections. However, more
in vitro, in vivo, and clinical studies are needed to elucidate the
applicability of PlyC for GAS biofilm eradication in patients.
Next to this endolysin, other substances with known broad
antibacterial properties have been shown to inhibit GAS biofilms.
Of special interest could be manuka honey that is available as ster-
ilized medical grade honey (medihoney) for topic wound treat-
ment. Maddocks and others described medihoney to inhibit the
expression of sof and sfb1 genes encoding for fibronectin binding
streptococcal surface proteins, resulting in reduced human tissue
binding and biofilm formation capacity (Maddocks et al., 2012).
It has to be considered that these findings have been reported only
for one clinical isolate representing anM28 serotype (MGAS6180;
M28). It remains to be seen if these effects are transferable to other
strains/emm genotypes, since there are remarkable differences of
the regulatory networks reported as discussed above.
It has furthermore been shown that the fatty acid messen-
ger cis-2-decenoic acid produced by Pseudomonas aeruginosa can
induce dispersion of biofilms of GAS and other bacteria. If such
substances could be administered in patients in combination with
conventional antibiotics, this would probably lead to eradication
of GAS biofilm associated infections (Davies andMarques, 2009).
Beside the chemical treatment of mature GAS biofilms, also
probiotic effects of physiological bacteria on GAS biofilm forma-
tion have been reported (Guglielmetti et al., 2010a,b; Fiedler et al.,
2013). It has been shown that bacteria physiologically coloniz-
ing the upper respiratory tract, such as Streptococcus oralis and
Streptococcus salivarius, protect epithelial cells from GAS adher-
ence. This observation indicates a role of these bacteria in host
health. It was reported that S. oralis could induce protection of
eukaryotic cells even without largely binding to the cells or pro-
ducing bacteriocins affecting GAS (Fiedler et al., 2013). Further
on, S. salivarius was shown to provide host cell protection against
GAS by forming an impermeable biofilm so the host epithelial
cells are inaccessible for initial GAS tissue colonization (Fiedler
et al., 2013). Other authors stated S. salivarius K12 to antago-
nize GAS growth by expressing the lantibiotics salivarin A2 and B
subsequently influencing GAS biofilm formation (Di et al., 2013,
2014).
CONCLUSION
The standard antibiotic medication for patients with GAS infec-
tions is not sufficient to eradicate GAS biofilms. Alternative or
additional therapeutics are currently investigated. Phage lysin C
represents the most promising candidate for clinical application.
However, more efforts are needed in developing treatment strate-
gies to prevent extensive and repeated antibiotic treatment in
patients with biofilm associated recurrent GAS infections.
OUTLOOK AND FUTURE CHALLENGES
Due to the high tolerance of GAS biofilms toward antibiotics, GAS
biofilms are likely to be associated with antibiotic treatment fail-
ure in patients. Therefore, the major future challenge will be the
development of new therapeutic strategies to prevent the exten-
sive use of antibiotics on patients with recurrent GAS biofilm
associated infections. As can be seen from this review, we are just
at the beginning of understanding the GAS biofilm phenotype
and its relevance for GAS pathogenesis. Therefore, extensive fur-
ther studies on the biological processes involved in GAS biofilm
formation are necessary.
A major question in this context is which environmental fac-
tors trigger GAS biofilm formation. It is highly likely that apart
from carbon source, external pH, and peptide pheromone levels,
host innate immune responses trigger GAS biofilm development
in vivo. Furthermore, more efforts are needed to decipher the role
of individual virulence factors and gene regulation circuits in GAS
biofilm development in vivo, since most of the current knowledge
is based on in vitro data.
Since the GAS biofilm formation capacity is very strain spe-
cific, it will be important to include the determination of the
biofilm phenotype of GAS strains into epidemiological investiga-
tions. Particularly the relation of the biofilm phenotype to other
parameters frequently studied in GAS epidemiology, e.g., emm-
or FCT-type, antibiotic resistance or presence/absence of certain
virulence factors, needs to be elucidated. Ideally, such studies will
lead to phenotypic profiles that will allow deducing the potential
of GAS isolates for biofilm formation.
Such tools would facilitate the specific treatment of patients
with recurrent infection potentially associated with GAS biofilms.
The most promising candidates for clinical application in GAS
biofilm eradication in patients are specific phage lysins such as
PlyC, since they have excellent MBEC values. Research in this area
should be intensified toward application in clinical practice.
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